Sign in
TerminatedPhase 1/2

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Key facts

Who runs it
University of Michigan Rogel Cancer Center
Where
Ann Arbor, Columbus, and St Louis, United StatesSee the 3 sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
25 people enrolled
Started
24 Dec 2018
Ended
1 May 2025
Type of study
Interventional
Treatments tested
  • Pembrolizumab
  • Pemetrexed
  • Carboplatin
  • Rucaparib
Record updated
12 February 2026
Why it stopped
Due to financial hardships suffered by the stakeholder

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Be willing and able to provide written informed consent/assent for the trial
  • Be ≥18 years of age on day of signing informed consent
  • Have a life expectancy of at least 3 months
  • Have a diagnosis of stage IV non-squamous NSCLC whose tumors do not have an epidermal sensitizing growth factor (EGFR) mutation or BRAF mutation or rearrangements in ALK (anaplastic lymphoma kinase) or ROS-1 and have at least one measurable lesion based on RECIST v1.1
  • Have a performance status of 0 or 1 on the ECOG Performance Scale (Appendix 15.1)
  • Demonstrate adequate organ function
  • Female subject of childbearing potential should have a serum pregnancy test within -28 days of enrollment and 72 hours prior to receiving the first dose of study medications
  • Female subjects of childbearing potential must be willing to use a highly effective method of contraception as outlined in Section 6.3.3 for the course of the study through 180 days after the last dose of study medications. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 6.3.3, starting with the first dose of study therapy through 180 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • If the patient has archival tissue, this should be collected for correlative studies. If archival tissue does not exist, a new biopsy is not required

Who cannot take part

  • Received previous systemic therapy for stage IV NSCLC
  • Received radiation to the lungs >30Gy ≤6 months of enrollment
  • Received palliative radiation within 7 days of enrollment
  • Had prior treatment with any other anti-PD-1, PD-L1, or PD-L2 agent or an antibody targeting other immune-regulatory receptors or mechanisms
  • Received prior treatment with a PARP inhibitor
  • Subjects requiring daily corticosteroids >10mg of prednisone (or its equivalent) would be excluded from the study
  • Has a diagnosis of immunodeficiency (including Human Immunodeficiency Virus (HIV) or acquired immunodeficiency (AIDS)-related illness) or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment
  • Has received a live vaccine within 30 days of enrollment
  • Has a known history of prior malignancy except if the patient has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy
  • Has active autoimmune disease that has required systemic treatment within the past 2 years
  • Has evidence of interstitial lung disease or a history of non-infectious pneumonitis that required oral or intravenous glucocorticoids to assist with management
  • Has an active infection requiring systemic therapy
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Has a known history of active TB (Bacillus Tuberculosis)
  • Has known active Hepatitis B or Hepatitis C
  • A medical condition that requires daily systemic corticosteroids, greater than the equivalent of 10mg of prednisone
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment

Where in United States

  • The University of Michigan Rogel Cancer CenterAnn Arbor, United States
  • Ohio State University Comprehensive Cancer CenterColumbus, United States
  • Washington University School of MedicineSt Louis, United States

About the trial

What the trial wants to find out

This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive disease (PD), as confirmed on CT scans, after induction therapy with carboplatin/pemetrexed/pembrolizumab (CPP) triplet therapy.

The group in the trial

  • Rucaparib and Pembrolizumab MaintenanceTreatment being tested

    All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m\^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days). This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle).

    Treatment: Pembrolizumab, Pemetrexed, Carboplatin, and Rucaparib

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
Record updated
12 February 2026